IBA gets OK for U.K. PET facility

AuntMinnie.com staff writers
Jul 2, 2007

Radioisotope manufacturer Ion Beam Applications (IBA) has received approval from U.K. officials to begin the manufacture of radiopharmaceuticals at its new PET production facility in Dinnington, South Yorkshire.

The Louvain-la-Neuve, Belgium-based vendor now has 35 PET production centers around the world, 17 of which are in Europe.

By AuntMinnie.com staff writers
July 3, 2007

Related Reading

IBA opens Beijing office, June 18, 2007

IBA begins European I-124 shipments, June 4, 2007

IBA opens Korea proton therapy center, May 16, 2007

IBA adds a 35th production center, May 10, 2007

IBA opens new radiotracer site, April 20, 2007

Copyright © 2007 AuntMinnie.com

Latest in Molecular Imaging
Isotopes1
Shine CEO: Chrysalis to be world’s largest medical isotope producer
July 3, 2024
Introducing Biograph Trinion™ PET/CT
Sponsored
Introducing Biograph Trinion™ PET/CT
June 10, 2024
Prostate
PSMA-PET superior to MRI in phase II prostate cancer trial
July 1, 2024
Brain Theranostics2
New guideline covers theranostics in brain tumors
June 21, 2024
Related Stories
187x200 Am Logo
Companies
AuntMinnie.com
2007 06 25 10 54 15 706
Molecular Imaging
Studies link Alzheimer's to beta-amyloid and potential for new ligand
2007 06 14 14 00 18 706
Molecular Imaging
UPenn study awarded SNM Small Animal Image of the Year
Introducing Biograph Trinion™ PET/CT
Sponsor Content
Introducing Biograph Trinion™ PET/CT
More in Molecular Imaging
Shine CEO: Chrysalis to be world’s largest medical isotope producer
By Will Morton
Greg Piefer, PhD, founder and CEO of Shine Technologies, says the company is two years away from launching world’s largest medical isotope facility.
July 3, 2024
Isotopes1
FDG-PET/CT improves management of patients with head and neck cancer
By Will Morton
FDG-PET/CT imaging can reduce unnecessary surgeries in patients to remove residual neck cancer after they have undergone chemoradiotherapy.
July 2, 2024
Headandneck
PSMA-PET superior to MRI in phase II prostate cancer trial
By Will Morton
PET/CT imaging with a new radiotracer is superior to MRI prior to surgery in men with intermediate-risk and high-risk prostate cancer.
July 1, 2024
Prostate
New guideline covers theranostics in brain tumors
By Will Morton
U.S. and European experts have proposed a joint practice guideline for use in nuclear medicine on diagnostics and therapy (theranostics) of meningiomas.
June 21, 2024
Brain Theranostics2
FCH-PET/CT superior to MIBI-SPECT/CT for guiding parathyroid surgery
By Will Morton
F-18 fluorocholine (FCH) PET/CT could be a first-line technique over technetium-99m sestamibi SPECT/CT for imaging parathyroid tumors prior to surgery.
June 20, 2024
(A) FCH-PET maximum-intensity projection; (B) FCH-PET/CT fusion transverse slice; and (C) low-dose CT transverse slice, showing high FCH uptake in an 11-mm left inferior parathyroid adenoma (arrowheads). The patient underwent minimally invasive parathyroidectomy, leading to normocalcemia during follow-up. No complications occurred.
PET sheds light on opioid addiction treatments
By Will Morton
PET imaging shows different brain activity in people taking methadone or buprenorphine for opioid use disorder (OUD).
June 19, 2024
C-11 carfentanil PET brain images in the sagittal plane (left column) and multiple transaxial planes (2nd through 4th columns) are shown on the left side. Red arrows indicate brain stem (1st column), amygdala (2nd column), and ventral tegmentum (3rd column). Experimental group descriptions are shown on the right (top) along with Logan distribution volume ratio (DVR) volumes of interest (VOI) means and coefficient of variances (CV) with percent change compared with the healthy control (HC) mean (%Diff). P-values (Mann-Whitney U test) are also provided. The VOI DVRs are plotted in the bottom right graph.
PET/CT shows promise detecting early atherosclerosis
By Will Morton
PET/CT imaging with F-18 sodium fluoride is emerging as a sensitive tool for detecting early atherosclerosis.
June 18, 2024
Athero
Alzheimer’s disease risk linked to maternal history of dementia
By Will Morton
PET scans show that people with mothers with a history of memory impairment had higher levels of brain-amyloid plaque associated with Alzheimer’s.
June 17, 2024
Ad
New PET tracer visualizes drivers of chronic pain
By Will Morton
A recently developed PET radiotracer identified sources of pain in patients with complex regional pain syndrome (CRPS) and led to effective treatments.
June 14, 2024
F-18 FTC-146 PET/MRI scan of a 21-year-old male soccer player who participated in the trial. The man had chronic bilateral lower expremity pain with a baseline pain score of 8 out of 10. Based on the finding, the patient underwent anesthetic injections and nerve blocks at the site of radiotracer uptake and reported a pain score of two on a follow-up visit.
SNMMI: PET/CT illuminates connection between CVD and cognitive impairment
By Kate Madden Yee
PET/CT reveals a connection between cardiovascular disease (CVD) and cognitive impairment, according to research presented at SNMMI 2024.
June 12, 2024
Brain Puzzle Dementia
SNMMI: PET-based protocol shows promise in radioligand therapy
By Amerigo Allegretto
A PET-based scout dosimetry protocol can be feasible in treating lesions with yttrium-90 FAPI (Y-90 FAPI) radioligand therapy.
June 12, 2024
Lesion uptake from a patient with a solitary fibrous tumor and its FAP expression on gallium-68 (GA-68)-FAPI-46 (A) and intratherpeutic Y-90-FAPI-46 (B). The panel shows the constructed time activity curve with the three PET/CT measurements.
Reduced gadolinium dose still produces effective meningioma images
By Kate Madden Yee
Gadolinium used for MRI can be reduced by more than half the standard dose level and still distinguish meningiomas from surrounding tissues.
June 11, 2024
Gadolinium
Page 1 of 594
Next Page